LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Patel, Nilesh; Taki, Mohammed; Tunstell, Paul; Forsey, Paul; Forbes, Ben (2012)
Publisher: BMJ
Languages: English
Types: Article
Subjects:
Objectives A pharmacy Central Intravenous Additives Service (CIVAS) provides ready to use injectable medicines. However, manipulation of a licensed injectable medicine may significantly alter the stability of drug(s) in the final product. The aim of this study was to develop a stability indicating assay for CIVAS produced dobutamine 500 mg in 50 ml dextrose 1% (w/v) prefilled syringes, and to allocate a suitable shelf life.\ud \ud Methods A stability indicating high performance liquid chromatography (HPLC) assay was established for dobutamine. The stability of dobutamine prefilled syringes was evaluated under storage conditions of 4°C (protected from light), room temperature (protected from light), room temperature (exposed to light) and 40°C (protected from light) at various time points (up to 42 days).\ud \ud Results An HPLC method employing a Hypersil column, mobile phase (pH=4.0) consisting of 82:12:6 (v/v/v) 0.05 M KH2PO4:acetonitrile:methanol plus 0.3% (v/v) triethylamine with UV detection at λ=280 nm was specific for dobutamine. Under different storage conditions only samples stored at 40°C showed greater than 5% degradation (5.08%) at 42 days and had the shortest T95% based on this criterion (44.6 days compared with 111.4 days for 4°C). Exposure to light also reduced dobutamine stability. Discolouration on storage was the limiting factor in shelf life allocation, even when dobutamine remained within 5% of the initial concentration.\ud \ud Conclusions A stability indicating HPLC assay for dobutamine was developed. The shelf life recommended for the CIVAS product was 42 days at 4°C and 35 days at room temperature when protected from light.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. Brunton LL, Blumenthal D, Buxton I et al. Goodman & Gilman's manual of pharmacology and therapeutics, 11th Edn. New York: McGraw-Hill Medical, 2008.
    • 2. NPSA Safety Alert 20: 0434-Promoting safer use of injectable medicines. NPSA/2007/20, 2007. http://www.nrls.npsa.nhs.uk/resources/?entryid45=59812 (accessed 30 March 2011).
    • 3. Needle R. Sizer T eds. The CIVAS Handbook: Centralised Intravenous Additive Services. London: Pharmaceutical Press, 1998.
    • 4. Bishara RH, Long HB. Dobutamine. In: Florey K ed. Analytical profiles of drug substances, 8th vol. New York: Academic Press, 1979.
    • 5. Pramar Y, Das Gupta V, Gardner SN, et al. Stabilities of dobutamine, dopamine, nitroglycerin and sodium nitroprusside in disposable plastic syringes. J Clin Pharm Ther 1991;16:203-7.
    • 6. Webster AA, English BA, McGuire JM, et al. Stability of dobutamine hydrochloride 4 mg/ml in 5% dextrose injection at 5°C and 23°C. Int J Pharm Comp 1999;3:412-14.
    • 7. Sautou-Miranda V, Gremeau I, Chamard I, et al. Stability of dopamine hydrochloride and of dobutamine hydrochloride in plastic syringes and administration sets. Am J Health Syst Pharm 1996;53:186-93.
    • 8. Gora ML, Seth S, Visconti JA, et al. Stability of dobutamine hydrochloride in peritoneal dialysis solutions. Am J Hosp Pharm 1991;48:1234-7.
    • 9. Husseini H, Mitrovic V, Schlepper M. Rapid and sensitive assay of dobutamine in plasma by high-performance liquid chromatography and electrochemical detection. J Chromatogr 1993;620:164-8.
    • 10. Leflour C, Dine T, Luyckx M, et al. Solid phase extraction and high performance liquid chromatographic determination of dobutamine in plasma of dialysed patients. Biomed Chromatogr 1994;8:309-12.
    • 11. ICH Topic Q 1 A (R2). Note for guidance on stability testing:stability testing of new drug substances and products (CPMP/ICH/2736/99). EMEA, 2003.
    • 12. Kirschenbaum HL, Aronoff W, Perentesis GP, et al. Stability of dobutamine hydrochloride in selected large-volume parenterals. Am J Hosp Pharm 1982;39:1923-5.
    • 13. Thompson M, Smith M, Gragg R, et al. Stability of nitroglycerin and dobutamine in 5% dextrose and 0.9% sodium chloride injection. Am J Hosp Pharm 1985;42:361-2.
    • 14. Allwood MC. The stability of four catecholamines in 5% glucose infusions. J Clin Pharm Ther 1991;16:337-40.
    • 15. Bakshi M, Singh B, Singh A, et al. The ICH guidance in practice: stress degradation studies on ornidazole and development of a validated stabilityindicating assay. J Pharm Biomed Anal 2001;26:891-7.
    • 16. Tuttle RR, Mills J. Dobutamine: development of a new catecholamine to selectively increase cardiac contractility. Circ Res 1975;36:185-96.
    • 17. Bindoli A, Rigobello MP, Deeble DJ. Biochemical and toxicological properties of the oxidation products of catecholamines. Free Radic Biol Med 1992;13:391-405.
    • 18. Remião F, Milhazes N, Borges F, et al. Synthesis and analysis of aminochromes by HPLC-photodiode array. Adrenochrome evaluation in rat blood. Biomed Chromatogr 2003;17:6-13.
  • No related research data.
  • No similar publications.

Share - Bookmark

Cite this article